Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus platinum-based chemotherapy versus chemotherapy alone in recurrent and/or metastatic squamous cell carcinoma of the head and neck
2004-001667-22Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Started Sep 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2004-001667-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001667-22.